Does the media prefer TVRD or SXTP?

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.96 beat 60 Degrees Pharmaceuticals' score of 0.48 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KPTI or SXTP more profitable?

Karyopharm Therapeutics has a net margin of -153.28% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -153.28% N/A -145.18% 60 Degrees Pharmaceuticals -650.21% N/A -136.81%

Do analysts rate SXTP or BFRI?

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, indicating a potential upside of 1,438.89%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer SXTP or BFRI?

In the previous week, Biofrontera had 2 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 7 mentions for Biofrontera and 5 mentions for 60 Degrees Pharmaceuticals. Biofrontera's average media sentiment score of 0.88 beat 60 Degrees Pharmaceuticals' score of 0.48 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biofrontera 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SXTP or CTXR?

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Citius Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.48 beat Citius Pharmaceuticals' score of 0.46 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

60 Degrees Pharmaceuticals (SXTP) Competitors

$0.88 -0.02 (-2.44%)

As of 11:32 AM Eastern

Compare

SXTP vs. TVRD, KPTI, CLRB, BFRI, and CTXR

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? 60 Degrees Pharmaceuticals's main competitors and comparable companies include Tvardi Therapeutics (TVRD), Karyopharm Therapeutics (KPTI), Cellectar Biosciences (CLRB), Biofrontera (BFRI), and Citius Pharmaceuticals (CTXR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 60 Degrees Pharmaceuticals compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Tvardi Therapeutics presently has a consensus target price of $9.40, suggesting a potential upside of 803.85%. 60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 1,438.89%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.96 beat 60 Degrees Pharmaceuticals' score of 0.48 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tvardi Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	1.94	-$18.21M	-$2.79	N/A
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$4.82	N/A

Tvardi Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market.

Summary

Tvardi Therapeutics beats 60 Degrees Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, 60 Degrees Pharmaceuticals had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.82 beat 60 Degrees Pharmaceuticals' score of 0.48 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Very Positive
60 Degrees Pharmaceuticals	Neutral

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Karyopharm Therapeutics has a net margin of -153.28% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

Karyopharm Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 2,590.69%. 60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 1,438.89%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Karyopharm Therapeutics is more favorable than 60 Degrees Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.07	-$196.04M	-$13.09	N/A
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$4.82	N/A

Karyopharm Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market.

Summary

Karyopharm Therapeutics beats 60 Degrees Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Cellectar Biosciences?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, suggesting a potential upside of 1,438.89%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 691.37%. Given 60 Degrees Pharmaceuticals' higher probable upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, 60 Degrees Pharmaceuticals had 4 more articles in the media than Cellectar Biosciences. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.27 beat 60 Degrees Pharmaceuticals' score of 0.48 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Neutral
Cellectar Biosciences	Positive

Cellectar Biosciences has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Cellectar Biosciences	N/A	-185.35%	-115.42%

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

60 Degrees Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$4.82	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

60 Degrees Pharmaceuticals has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

Cellectar Biosciences beats 60 Degrees Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Biofrontera?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

60 Degrees Pharmaceuticals has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

60 Degrees Pharmaceuticals has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$4.82	N/A
Biofrontera	$41.71M	0.32	-$10.54M	-$0.45	N/A

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, indicating a potential upside of 1,438.89%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biofrontera had 2 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 7 mentions for Biofrontera and 5 mentions for 60 Degrees Pharmaceuticals. Biofrontera's average media sentiment score of 0.88 beat 60 Degrees Pharmaceuticals' score of 0.48 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biofrontera	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 8.1% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biofrontera has a net margin of -13.78% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Biofrontera	-13.78%	-145.81%	-31.30%

Summary

Biofrontera beats 60 Degrees Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Citius Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, indicating a potential upside of 1,438.89%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 950.42%. Given 60 Degrees Pharmaceuticals' higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 5 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Citius Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.48 beat Citius Pharmaceuticals' score of 0.46 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60 Degrees Pharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$4.82	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

60 Degrees Pharmaceuticals has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Citius Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

Summary

60 Degrees Pharmaceuticals beats Citius Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTP vs. The Competition

Export

Metric	60 Degrees Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.11M	$12.35B	$7.25B	$13.04B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-0.18	807.81	275.44	25.51
Price / Sales	2.19	748.69	562.05	79.58
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	-0.15	9.26	10.64	6.00
Net Income	-$7.36M	$2.83B	$3.49B	$380.50M
7 Day Performance	-20.18%	-3.62%	-3.21%	-3.35%
1 Month Performance	-2.28%	-7.66%	-7.65%	-6.23%
1 Year Performance	-87.81%	-5.44%	2.92%	-3.96%

60 Degrees Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTP 60 Degrees Pharmaceuticals	2.6959 of 5 stars	$0.88 -2.4%	$13.85 +1,477.4%	-86.0%	$3.11M	$1.41M	N/A	3	Short Interest Decrease Gap Down
TVRD Tvardi Therapeutics	3.7385 of 5 stars	$1.10 +1.9%	$18.00 +1,536.4%	-84.5%	$14.67M	$7.14M	N/A	80	News Coverage Analyst Downgrade
KPTI Karyopharm Therapeutics	3.5638 of 5 stars	$0.65 -0.8%	$11.50 +1,682.9%	-92.4%	$14.63M	$146.07M	N/A	228
CLRB Cellectar Biosciences	3.7301 of 5 stars	$1.51 flat	$11.00 +628.5%	-71.6%	$14.27M	N/A	N/A	11	Positive News Gap Up
BFRI Biofrontera	1.7501 of 5 stars	$0.94 +0.4%	N/A	-5.3%	$13.89M	$46.18M	N/A	94	Analyst Forecast Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. TVRD, KPTI, CLRB, BFRI, and CTXR

How does 60 Degrees Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to Karyopharm Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to Cellectar Biosciences?

Summary

How does 60 Degrees Pharmaceuticals compare to Biofrontera?

Summary

How does 60 Degrees Pharmaceuticals compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. TVRD, KPTI, CLRB, BFRI, and CTXR

How does 60 Degrees Pharmaceuticals compare to Tvardi Therapeutics?

Do analysts prefer TVRD or SXTP?

Do insiders & institutionals hold more shares of TVRD or SXTP?

Does the media prefer TVRD or SXTP?

Is TVRD or SXTP more profitable?

Which has stronger valuation and earnings, TVRD or SXTP?

Which has more volatility and risk, TVRD or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Karyopharm Therapeutics?

Does the media refer more to KPTI or SXTP?

Do insiders & institutionals hold more shares of KPTI or SXTP?

Is KPTI or SXTP more profitable?

Do analysts rate KPTI or SXTP?

Which has higher valuation and earnings, KPTI or SXTP?

Which has more volatility and risk, KPTI or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Cellectar Biosciences?

Do analysts prefer SXTP or CLRB?

Does the media prefer SXTP or CLRB?

Is SXTP or CLRB more profitable?

Do insiders and institutionals hold more shares of SXTP or CLRB?

Which has stronger earnings and valuation, SXTP or CLRB?

Which has more risk and volatility, SXTP or CLRB?

Summary

How does 60 Degrees Pharmaceuticals compare to Biofrontera?

Which has more risk and volatility, SXTP or BFRI?

Which has better valuation and earnings, SXTP or BFRI?

Do analysts rate SXTP or BFRI?

Does the media prefer SXTP or BFRI?

Do insiders & institutionals believe in SXTP or BFRI?

Is SXTP or BFRI more profitable?

Summary

How does 60 Degrees Pharmaceuticals compare to Citius Pharmaceuticals?

Do analysts recommend SXTP or CTXR?

Do insiders and institutionals believe in SXTP or CTXR?

Does the media prefer SXTP or CTXR?

Which has higher valuation & earnings, SXTP or CTXR?

Which has more volatility and risk, SXTP or CTXR?

Is SXTP or CTXR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools